Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.4869
-0.0290 (-5.62%)
At close: Sep 11, 2026, 4:00 PM EDT
0.4900
+0.0031 (0.64%)
After-hours: Sep 11, 2026, 7:53 PM EDT
Ensysce Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Announced the acquisition of Cy Biopharma and up to $77 million in financing to advance CY200, a novel therapy for CRPS, through key clinical milestones. Integration brings new leadership and extends cash runway into late 2027.
Fiscal Year 2025
-
The meeting approved all proposals, including share issuance, incentive plan amendment, director elections, and auditor ratification. Key product candidates advanced in clinical development, with strong financial and regulatory support positioning the company for a pivotal year ahead.